Catalyst Wire Dossier Catalyst Wire Dossier

XER-001

amifostine · Xerient Pharma
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XER-001, covering 2026-02-11 to 2026-02-11. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. [Phase 1, Phase 2]

See pricing